JP2020528449A5 - - Google Patents

Info

Publication number

JP2020528449A5

JP2020528449A5 JP2020519008A JP2020519008A JP2020528449A5 JP 2020528449 A5 JP2020528449 A5 JP 2020528449A5 JP 2020519008 A JP2020519008 A JP 2020519008A JP 2020519008 A JP2020519008 A JP 2020519008A JP 2020528449 A5 JP2020528449 A5 JP 2020528449A5

Authority

JP

Japan

Prior art keywords

composition

gastrin

cancer

tumor

patient

Prior art date

2018-06-15

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 claims description 29
• 239000000203 mixture Substances 0.000 claims description 23
• 108010052343 Gastrins Proteins 0.000 claims description 17
• 201000011510 cancer Diseases 0.000 claims description 13
• AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims description 13
• 239000008194 pharmaceutical composition Substances 0.000 claims description 6
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
• 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 4
• 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 4
• 206010027476 Metastases Diseases 0.000 claims description 4
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
• 230000009401 metastasis Effects 0.000 claims description 4
• 210000004027 cell Anatomy 0.000 claims description 3
• 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 3
• 102400000921 Gastrin Human genes 0.000 claims 6
• 230000002163 immunogen Effects 0.000 claims 4
• 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 3
• 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 3
• 239000002671 adjuvant Substances 0.000 claims 3
• 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
• 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
• 108010089448 Cholecystokinin B Receptor Proteins 0.000 claims 2
• 229950009791 durvalumab Drugs 0.000 claims 2
• 238000000034 method Methods 0.000 claims 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
• 230000004044 response Effects 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 claims 1
• 206010016654 Fibrosis Diseases 0.000 claims 1
• 102000052874 Gastrin receptors Human genes 0.000 claims 1
• 102100036016 Gastrin/cholecystokinin type B receptor Human genes 0.000 claims 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
• 150000001413 amino acids Chemical group 0.000 claims 1
• 229960003852 atezolizumab Drugs 0.000 claims 1
• 229950002916 avelumab Drugs 0.000 claims 1
• 230000004071 biological effect Effects 0.000 claims 1
• 230000015572 biosynthetic process Effects 0.000 claims 1
• 229940098773 bovine serum albumin Drugs 0.000 claims 1
• 229960003983 diphtheria toxoid Drugs 0.000 claims 1
• 230000004761 fibrosis Effects 0.000 claims 1
• 239000000411 inducer Substances 0.000 claims 1
• 239000003112 inhibitor Substances 0.000 claims 1
• 229960005386 ipilimumab Drugs 0.000 claims 1
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 1
• 230000021633 leukocyte mediated immunity Effects 0.000 claims 1
• 239000003446 ligand Substances 0.000 claims 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
• 229960003301 nivolumab Drugs 0.000 claims 1
• 201000002528 pancreatic cancer Diseases 0.000 claims 1
• 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
• 229960002621 pembrolizumab Drugs 0.000 claims 1
• 229920001184 polypeptide Polymers 0.000 claims 1
• 108090000765 processed proteins & peptides Proteins 0.000 claims 1
• 102000004196 processed proteins & peptides Human genes 0.000 claims 1
• 230000001235 sensitizing effect Effects 0.000 claims 1
• 230000011664 signaling Effects 0.000 claims 1
• 229960000814 tetanus toxoid Drugs 0.000 claims 1
• 229950007217 tremelimumab Drugs 0.000 claims 1
• 102100021022 Gastrin Human genes 0.000 description 6
• 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
• 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 108010063604 gastrin immunogen Proteins 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1